Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BOLD | 8-K | neutral | 3/10 | Boundless Bio reported Q1 2026 results with a net loss of $13.6M, narrower than the $15.8M loss in Q1 2025, driven by lo | May 8, 2026 |
| ANIP | 8-K | bullish | 8/10 | ANI Pharmaceuticals reported Q1 2026 revenue of $237.5M (+20.5% YoY) and GAAP diluted EPS of $1.28, beating consensus es | May 8, 2026 |
| ANIP | PRESS-RELEASE | bullish | 8/10 | ANI Pharmaceuticals reported Q1 2026 adjusted non-GAAP diluted EPS of $2.05, beating the $1.30 consensus by 57.7%, on re | May 8, 2026 |
| ARTV | 8-K | bullish | 8/10 | Artiva reported Q1 2026 net loss of $23.5M ($0.95/share), slightly wider than the $20.3M loss a year ago, with cash burn | May 8, 2026 |
| ARTV | PRESS-RELEASE | bullish | 7/10 | Artiva reported Q1 2026 GAAP EPS of -$0.95, missing the Street consensus of -$0.84 by 13.1%, while revenue remained $0. | May 8, 2026 |
| ARTV | PRESS-RELEASE | bullish | 7/10 | Artiva Biotherapeutics announced positive initial Phase 2a data for AlloNK in refractory RA, showing 71% ACR50 at six mo | May 8, 2026 |
| ODTX | EFFECT | mixed | 6/10 | Odyssey Therapeutics' IPO registration (S-1) became effective on May 7, 2026, clearing the final regulatory hurdle for t | May 8, 2026 |
| CMND | EFFECT | bearish | 6/10 | Clearmind Medicine's registration statement on Form F-3 (File No. 333-295455) was declared effective by the SEC on May 7 | May 8, 2026 |
| TERN | EFFECT | neutral | 4/10 | Terns Pharmaceuticals' automatic shelf registration statement (S-3ASR) filed on December 9, 2025, became effective on Ma | May 8, 2026 |
| ONCO | EFFECT | bearish | 7/10 | The SEC declared effective Onconetix's S-1 registration (File No. 333-295376), enabling Keystone Capital Partners to imm | May 8, 2026 |
| IMRN | 6-K | neutral | 4/10 | Immuron reported 3Q FY2026 global sales of A$1.5M (+16% YoY) and YTD sales of A$5.7M (+7% YoY), with Australian sales up | May 8, 2026 |
| LODE | 8-K | neutral | 3/10 | Comstock Inc. reported Q1 2026 results and corporate updates, highlighting a $57.5M equity financing, cash of $53M, and | May 8, 2026 |
| CLRB | 8-K | bearish | 8/10 | Cellectar Biosciences files securities purchase agreements for a massive $34.95M registered direct offering with 300% wa | May 8, 2026 |
| BBIO | S-3ASR | mixed | 6/10 | BridgeBio Pharma filed an automatic shelf registration (S-3ASR) to register an unlimited amount of securities, including | May 8, 2026 |
| PHVS | PRESS-RELEASE | bearish | 6/10 | Pharvaris priced a $115M underwritten offering of 3.87M shares at $29.68 per share, representing ~6% dilution. The capit | May 8, 2026 |
| BIIB | PRESS-RELEASE | bearish | 6/10 | Biogen and Eisai announced a 3-month FDA review extension for the sBLA of LEQEMBI IQLIK (once-weekly subcutaneous inject | May 8, 2026 |
| ODTX | 3 | neutral | 2/10 | Timothy P. Walbert filed a Form 3 initial statement of beneficial ownership with the SEC upon becoming an insider of Ody | May 7, 2026 |
| ODTX | 3 | neutral | 2/10 | Odyssey Therapeutics filed two Form 3 initial beneficial ownership statements for new insiders Ourania Tatsis and Valeri | May 7, 2026 |
| ODTX | 3 | neutral | 2/10 | Jolie M. Siegel filed a Form 3 initial beneficial ownership report upon becoming Executive Vice President, General Couns | May 7, 2026 |
| ODTX | 3 | neutral | 2/10 | Jeffrey M. Leiden filed a Form 3 initial statement of beneficial ownership with the SEC, reporting direct and indirect h | May 7, 2026 |
| ODTX | 3 | neutral | 2/10 | Simeon George and SR One Capital Management, LLC filed a Form 3 initial statement of beneficial ownership for Odyssey Th | May 7, 2026 |
| ODTX | 3 | neutral | 2/10 | Ian F. Smith filed a Form 3 initial statement of beneficial ownership with the SEC, reporting direct ownership of 246,10 | May 7, 2026 |
| ODTX | 3 | neutral | 1/10 | Carolyn Ng filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting no securities beneficiall | May 7, 2026 |
| ODTX | 3 | neutral | 2/10 | Paulina Hill filed a Form 3 initial statement of beneficial ownership with the SEC for Odyssey Therapeutics, Inc. (ODTX) | May 7, 2026 |
| ODTX | PRESS-RELEASE | neutral | 5/10 | Odyssey Therapeutics priced its upsized IPO of 15.5M shares at $18.00/share, with a concurrent private placement of 1.39 | May 7, 2026 |
| LONA | 3 | neutral | 2/10 | Natalie C. Holles filed an initial statement of beneficial ownership (Form 3) with the SEC, indicating her status as an | May 7, 2026 |
| CPRX | DEFA14A | bullish | 8/10 | Catalyst Pharmaceuticals (CPRX) filed additional proxy soliciting materials for its pending acquisition by Angelini Phar | May 7, 2026 |
| KALA | S-3 | neutral | 2/10 | KALA BIO filed an S-3 shelf registration to issue an unlimited amount of senior and subordinated debt securities. The fi | May 7, 2026 |
| JBIO | S-3 | bearish | 7/10 | Jade Biosciences filed an S-3 resale registration for up to 39.5M shares held by selling stockholders (57.9% of outstand | May 7, 2026 |
| SHPH | 8-K | bearish | 8/10 | Shuttle Pharmaceuticals completed its merger with United Dogecoin Inc., transforming into a crypto mining company. Exist | May 7, 2026 |